An immunohistochemical study of the expression of p53 protein in colon cancer.
10.3346/jkms.1995.10.3.176
- Author:
Youn Wha KIM
1
;
Sun LEE
;
Jae Hoon PARK
;
Tai Young YOON
;
Yong Koo PARK
;
Moon Ho YANG
Author Information
1. Department of Pathology, College of Medicine, Kyung Hee University, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Colon;
Adenocarcinoma;
p53;
Immunohistochemistry;
Prognosis
- MeSH:
Adenocarcinoma/*chemistry;
Adenoma/*chemistry;
Adult;
Colonic Neoplasms/*chemistry/mortality;
Female;
Formaldehyde;
Human;
Immunohistochemistry;
Male;
Middle Age;
Multivariate Analysis;
Prognosis;
Protein p53/*analysis;
Support, Non-U.S. Gov't;
Survival Analysis;
Tumor Markers, Biological/*analysis
- From:Journal of Korean Medical Science
1995;10(3):176-182
- CountryRepublic of Korea
- Language:English
-
Abstract:
A total of 471 cases of colonic adenocarcinomas and 28 cases of colonic adenomas were examined immunohistochemically to evaluate the expression of p53 protein in the light of their relationship with various prognostic factors. A monoclonal antibody, p53 DO-7, was used in the study. Two hundred and fourteen adenocarcinomas (45.5%) showed positive staining for p53, however only three of the adenomas (10.3%) were positive (P < 0.05). p53 was stained to neoplastic nuclei. Adjacent normal mucosal cells were negative. There were no significant correlations between p53 expression and prognostic parameters such as age, sex, gross configuration, modified Astler-Coller stages, microscopic tumor growth patterns, tumor depth, tumor size and lymph node involvements. However, left sided adenocarcinomas (49.3%) expressed p53 more often than right sided adenocarcinomas (35.6%) (P = 0.01). The positive rates were different according to the histologic differentiation; 45.2% in well differentiated, 51.3% in moderately well differentiated, 23.8% in poorly differentiated, and 26.5% in mucinous carcinomas (P = 0.011). The mean survival periods of the p53 positive and negative groups were 29 months and 32 months, respectively (P = 0.385). However, overall survival for patients with grade one and two positive p53 was better than those of grade three and four positive cases (P = 0.028). In conclusion, the result of this multivariate analysis suggests that immunohistochemically strong p53 protein expression (more than 30% of tumor cells) has value in estimating a prognosis for patients with colorectal adenocarcinomas.
